6th Dec 2021 10:44
(Alliance News) - Hutchmed (China) Ltd has completed patient enrolment for a study into metastatic colorectal cancer drug Fruquintinib, the pharmaceutical firm said Monday.
Hong-Kong based Hutchmed completed enrolment of Fresco-2, a phase III registration study of the investigational drug for patients in the US, Europe, Japan and Australia.
The study is a randomised, placebo-controlled, multicenter trial being conducted in patients with metastatic colorectal cancer, Hutchmed said. The primary endpoint of the study is overall survival, with the trial enrolling patients from over 150 sites in 14 countries.
Marek Kania, Hutchmed managing director & chief medical officer commented: "Hutchmed continues to execute on developing novel oncology medicines for patients worldwide despite the backdrop of the global pandemic".
Topline results from the Fresco-2 trial are expected to be reported in the second half of 2022.
Hutchmed shares were down 5.7% to 479.00 pence each in London on Monday morning.
By Will Paige; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
Hutchmed